Business Wire

Mori Memorial Foundation Issues GPCI–2024 and GPCI–Financial Centers Reports:

10.12.2024 04:00:00 CET | Business Wire | Press release

Share

— Post-Pandemic Economic Recovery and International Tourism Expansion Impact Rankings —

The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today released its Global Power City Index (GPCI) 2024 report on the overall strength of the world’s 48 major cities. For the second time, the report additionally includes the 'GPCI–Financial Centers' index. This index reflects the growing importance of measures taken by major cities to enhance their status as international financial centers, capturing changes in their financial and business environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209714811/en/

The 48 major cities evaluated in Mori Memorial Foundation’s GPCI–2024 Report (Graphic: Business Wire)

More than 18 months have elapsed since the World Health Organization declared an end to the COVID-19 pandemic in May 2023. With the resurgence of economic activity, mobility and the expansion of international tourism, this year’s GPCI rankings also reflect global trends influenced by the escalating issues of inflation and climate change.

There was no change in the top five rankings (London in 1st place, New York in 2nd, Tokyo in 3rd, Paris in 4th, and Singapore in 5th). However, Tokyo, Paris, and Singapore made substantial strides, closing in on New York's position; all three of those cities saw improvements in indicators related to “Cultural Interaction,” such as the number of foreign tourists and visitor amenities, including the number of hotel rooms. The decision to host the 2024 Summer Olympics in Paris, and the growth of international tourism in Tokyo and Singapore, which had been delayed due to cautious border control measures, were reflected in the results.

GPCI–2024 Highlights

London (1st)

While the momentum generated by London’s recovery from the pandemic eased compared to last year, the city’s overall score increased slightly, ensuring it maintained its top position. In addition to its overall lead in the “Cultural Interaction” function, London newly secured the first place in “Accessibility.” The city’s scores in “Livability” improved in indicators including “Working Environment,” rising to 6th place in this category. Continued improvements in London’s environmental indicators could potentially lead to a further increase in the city’s overall score.

New York (2nd)

New York held onto its second place, though its overall score declined from last year, widening the gap with London. It continues to excel in key areas, securing first place in both the "Economy" and "R&D" categories. The city's rank in the "Accessibility" function improved, particularly in the area of "Ease of Mobility by Bicycle." However, with the city ranked down in the 30s for both "Livability" and "Environment," there remains significant potential for improvement.

Tokyo (3rd)

Tokyo made substantial gains in its overall score this year, closing in on New York, with contributing factors including the rise in the number of foreign visitors taking advantage of a weaker yen. However, it is being closely pursued by Paris, which sits in fourth place, indicating tight competition. Tokyo saw improvements in four functions: “R&D,” “Cultural Interaction,” “Livability,” and “Accessibility,” achieving the largest score increase among all 48 cities this year. Despite these advancements, the city’s “Economy” function, which has been in relative decline, is noted as an area needing improvement.

Paris (4th)

Paris came within striking distance of Tokyo in third place. Nevertheless, the city saw a dramatic increase in its “Cultural Interaction” score, backed by its hosting of the Olympics, marking the largest increase in this category among the 48 cities. The full effects of the city’s hosting of the Olympics, such as an increase in the number of foreign visitors, will be reflected in GPCI-2025, suggesting the possibility of further score improvements.

Singapore (5th)

Although its recovery from the pandemic had been somewhat slow, Singapore managed to further boost its "Air Transport Capacity" ratings and enhance its performance in the "Cultural Interaction" and "Livability" functions, thereby maintaining its 5th place overall. In "Economy," it made significant gains in "GDP per Capita;" however, it saw a decline in areas previously considered its strengths, such as "Variety of Workplace Options," "Workstyle Flexibility" and "Number of Retail Shops.”

Seoul (6th)

Seoul made positive strides this year, moving up one place in the rankings thanks to improved scores in “R&D,” “Accessibility” and “Livability.” This was despite a decrease in the city’s overall score, due partially to a significant drop in its “Cultural Interaction” ratings. The city made notable progress in the “Commitment to Climate Action” indicator, which newly evaluates the frequency with which a city is selected for the CDP A List, achieving a substantial increase in ranking. Seoul's rise in the rankings was partly the result of Amsterdam, previously in 6th place, suffering falling ratings across five functions, excluding “Environment.”

Madrid (10th)

Madrid made a notable leap this year, climbing four places and re-entering the top 10 for the first time in three years. In addition to maintaining its second place in "Livability," the city saw improvements in "R&D," "Environment" and "Accessibility." Significant progress was observed in "Number of International Students" (R&D), "Commitment to Climate Action" and "Urban Greenery" (Environment), as well as in "Travel Time to Airports" and "Commuting Time" (Accessibility). However, there was a decline in the city’s ratings for "Variety of Workplace Options" and "Housing Rent."

Shanghai (11th)

In the wake of the lifting of border controls imposed during the COVID pandemic, Shanghai moved up from 15th to 11th place. This shift was largely influenced by the recovery of international travel. The city saw an increase in its “Number of Foreign Visitors” (Cultural Interaction) ranking as well as in “Number of Air Passengers,” which resulted in an improvement in “Accessibility,” pushing its ranking in this area from 9th up to 7th. Additionally, Shanghai's 12th position in “R&D” was strengthened by higher evaluations for its “World's Top Universities.”

Key Finding by Functions

Economy

Dublin and Copenhagen made significant strides in this category, fueled by a continued surge in their “GDP Growth Rate” scores. Dublin moved up from 6th to 3rd place, while Copenhagen leaped from 19th to 9th place.

R&D

American cities occupied five of the top 10 spots, reflecting their ongoing strengths. Among Asian cities, Tokyo, Seoul and Hong Kong made it into the top 10. Tokyo advanced one rank to 3rd place, a position it reclaimed after four years. Both Tokyo and Dubai, the latter now in 32nd place, saw significant score increases in the "Number of Startups" category.

Cultural Interaction

While London continues to hold its dominant position, Paris and Tokyo have made notable strides. Paris, moving up from 3rd to 2nd place, and Tokyo, rising from 5th to 3rd, saw a significant increase in scores including “Number of Foreign Visitors.”

Livability

The top four cities remain unchanged, with Paris in 1st place, followed by Madrid, Tokyo and Barcelona. Osaka, Milan, Helsinki and Kuala Lumpur newly entered the top 10. Changes in rankings were influenced by indicators such as inflation levels, as well as post-pandemic factors in areas including “Workstyle Flexibility.”

Environment

Eight out of the 10 highest-ranked cities were in Europe, five of which have populations of less than one million (Copenhagen, Stockholm, Helsinki, Zurich and Geneva). Factors such as “Commitment to Climate Action,” incorporating evaluations by the climate change initiative CDP, influenced the rankings.

Accessibility

There was a significant reshuffle of the top ten cities from last year in this category; they are now, in order, London, New York, Paris, Dubai, Tokyo, Frankfurt, Shanghai, Amsterdam, Singapore and Istanbul. This shift can be attributed to changes in the evaluation indicators used, such as the inclusion of the number of bicycle parking spaces and cycle ports under "Ease of Mobility by Bicycle." London in particular stood out in the category of "Cities with Direct International Flights."

GPCI–Financial Centers

The rapid expansion and internationalization of the global financial industry is intensifying competition among major cities, making each city’s status as an international financial center increasingly important. The Mori Memorial Foundation, in addition to its multifaceted evaluation of cities in terms of six functions in the Global Power City Index (GPCI), namely Economy, R&D, Cultural Interaction, Livability, Environment, and Accessibility, has now added the Finance function, which consists of 14 indicators in 4 groups.

New York (1st): the city received high scores across all groups of indicators - Financial Instruments Markets, Financial Intermediaries, Foreign Exchange and Interest Rate Markets, and Highly Skilled Personnel. As in the previous year, it ranked first in terms of “Stock Market Capitalization,” “Stock Market Trading Value,” “World’s Top Asset Managers,” and “International Law Firms.” This year it also ranked first in the “Financial Industry Unicorn Companies” category.

London (2nd): it maintained its position as the city with the highest level of “Foreign Exchange Turnover” and “Interest Rate Derivatives Turnover” in the Foreign Exchange and Interest Rate Markets category, and has a clear lead in this area. It also continued to secure the second-highest ratings for “Highly Skilled Personnel” in the finance sector, after New York.

Tokyo (3rd): Japan’s capital maintained its top ranking in two indicators of the Financial Intermediaries Group function: “World’s Top Insurance Company Headquarters” and “World’s Top Pension Funds.” It also maintained its high rankings for “Stock Market Capitalization” and “Stock Market Trading Value,” achieving 3rd and 4th place respectively. The city improved its ratings in the field of “Financial Instruments Markets,” rising from 9th to 4th position, due in part to an improvement in its score for “Capital Raised Through IPOs,” a category where it rose from 7th to 5th position.

Shanghai (4th): the city maintained its second place ranking in the category of Financial Instruments Markets for the second year in a row, but it fell from 7th to 23rd place in “Financial Industry Unicorn Companies;” it also recorded a reduced score in the specific area of Highly Skilled Personnel.

Beijing (5th): China’s capital city maintained its position in third place in Financial Instruments Markets and secured the top slot in the category of “World’s Top Bank Headquarters.” However, its ratings in its other perceived area of strength, Highly Skilled Personnel, fell with the city dropping from fifth to seventh place in this category.

The full press release can be viewed at https://mori-m-foundation.or.jp/pdf/GPCI2024_release_en.pdf

View source version on businesswire.com: https://www.businesswire.com/news/home/20241209714811/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye